2020 Annual SRNT-E Conference

15th - 17th Sep 2020

Conference Programme

Accordion Arrow

Download the 'At a glance' agenda below

The full PDF programme (inluding abstracts) is available for download here. You can also access the interactive programme on our conference platform Whova here.

The keynote speakers are programmed as follows, with all times in Cental European Summer Time (CEST):

17 September

12:00-12:45 (CEST) - Prof. Linda Bauld, chaired by Prof. Lynne Dawkins

15:15-16:00 (CEST) - Prof. Daniel Kotz, chaired by Prof. Ute Mons

18 September

12:00-12:45 (CEST) - Dr. Konstantinos Farsalinos, chaired by Prof. Lion Shahab

15:15-16:00 (CEST) - Prof. Billie Bonevski, chaired by Prof. Caitlin Notley


Read more about the topic of each keynote under 'Keynote Speakers' below.

Keynote Speakers

Accordion Arrow

Dr. Stéphanie Caillé-Garnier

Research Director at the French National Centre for Scientific Research (CNRS) and Institute for Cognitive and Integrative Neurosciences of Aquitaine, University of Bordeaux.

Dr. Caillé-Garnier obtained her doctorate in Neurosciences and Neuropharmacology from the University of Bordeaux in 2000. Upon joining the CNRS in 2005, the researcher's primary focus was on the consequences of chronic drug exposure in rodents, with a particular emphasis on nicotine, opioids, and the endocannabinoid system. Subsequently, she shifted the focus of her research to the investigation of predictive factors associated with vulnerability to addictive behaviors. As a Principal Investigator (PI) or co-investigator on several university and national agency funding projects, she elucidated the role of interindividual differences, whether attributable to sex differences, cognitive or emotional profiles, in the expression of vulnerability to drug of abuse.

Beyond her academic research, Dr. Caillé-Garnier has served as a national and international expert on public health and regulatory matters. Since 2017, she has contributed as a scientific expert to ANSES (French Agency for Food, Environmental and Occupational Health & Safety) in the working group on tobacco and vaping products. Furthermore, she was a key contributor to the European "Joint Action on Tobacco Control" from 2017 to 2020, where she helped shape science-based policy recommendations. 

Visit website External link icon

Luk Joossens

Senior Policy Advisor, Smoke Free Partnership, Brussels, Belgium

Keynote Title: Reflections on 50 years of tobacco control in Europe

Luk Joossens obtained a Licence de sociology, KU Leuven, Belgium, March 1972 and Maîtrise en sociologie, Sorbonne, Paris, November 1972. Since then, for almost 50 years he has contributed to the different aspects of tobacco control, such as the eight editions of the Tobacco Control Scale (2006-2026), passive smoking, advertising, labelling, taxes, smuggling (1995-2025), tracking and tracing, tobacco industry tactics, Belgian and EU tobacco control policy, FCTC, Protocol to eliminate illicit trade in tobacco products. 

Luk Joossens worked closely together with consumer organisations (1973-2003), Europe against Cancer progamme (1988-1995), International Union against Cancer (strategic leader 2006-2009), European Cancer Leagues (1995-2020), Belgian Foundation against Cancer (2003-2016). Framework Convention Alliance (2007-2012), Smoke Free Partnership (2022-2026). He advised extensively international bodies on tobacco control such as the World Health Organization (from 1990 to 2025), the World Bank, The European Commission and the FCTC secretariat. In 2006, he received the American Cancer Society “Luther Terry Award” for Outstanding Individual Leadership in Tobacco Control and in 2015 the World Health Organization Director-General’s Special Recognition of Contribution to Global Tobacco Control.

Visit website External link icon

Dr Cristina Martínez

Head of Cancer Prevention Programme and Tobacco Control Unit at the Catalan Institute of Oncology, University of Barcelona Associate Lecturer, Faculty of Nursing, University of Barcelona

Keynote title: Why Evidence Is Not Enough: Making Smoking Cessation Happen in Hospital Care

Dr. Martínez is a senior researcher in tobacco control and implementation science. Her main areas of research include the evaluation of tobacco control policies in health care services, by assessing the impact of smoke-free policies and evaluating the effectiveness of smoking cessation and training programs. She is currently developing and testing the effectiveness of tobacco cessation training programs among healthcare professional students, and she is also evaluating policy interventions to promote smoking cessation among vulnerable persons (mentally ill or with substance abuse disorders) and promoting smoke-free environments in private settings (homes).

Visit website External link icon

Dr Tessa Langley

Associate Professor in Public Health Economics and Evaluation, Nottingham Centre for Public Health and Epidemiology, University of Nottingham, UK

Keynote title: Beyond Health: The Economic and Equity Implications of Tobacco and Vaping Policies

Dr Tessa Langley is an Associate Professor in Public Health Economics and Evaluation. She completed an Honours degree in Economics and Economic History at the University of Warwick, followed by a Master’s in Public Health at the University of Nottingham, before continuing to a research role, PhD and subsequently an academic position at the University of Nottingham. She specialises in public health economics and evaluation, with a focus on tobacco control and e‑cigarette policy. She has led numerous studies evaluating tobacco control policies in the UK and assessing the economic impact of tobacco use, highlighting how reducing smoking rates not only improves health but also helps reduce economic inequalities. In addition to her research, Dr Langley is a member of the Royal College of Physicians’ Tobacco Advisory Group, contributing to regular evidence reviews on tobacco and nicotine policy, and serves as Deputy Editor of Nicotine & Tobacco Research.

Visit website External link icon

Posters and Symposia

Accordion Arrow

Posters:

Please see the full conference programme for information on posters, which can be downloaded from here.

Confirmed symposia:

Thursday 17th September 13.00-14.30 (CEST)

Evaluating the process and outcomes of implementing a national smokefree prisons policy across Scotland: study findings and lessons for other jurisdictions and high smoking prevalence groups

Objectives: To present findings from two complementary studies of tobacco and e-cigarette use in prison. The first is a multi-methods, 3-Phase comprehensive evaluation of the development, preparation for, implementation and outcomes of smokefree policy across Scotland’s prison system, known as the Tobacco in Prisons (TIPs) study. The second is a novel study of e-cigarette use in the prison population before and after implementation of the smokefree policy. Through these studies, we believe we provide the most in-depth evaluation internationally of a smokefree prison policy to date.  This evidence can inform transferable insights for other jurisdictions and high-smoking prevalence populations. 

By presenting papers using different methods (objective measurements of secondhand smoke (SHS); qualitative focus group/interview data and surveys with people in custody and prison staff; prisoner purchasing data), the workshop will demonstrate the success of implementing smokefree prison policy in Scotland and the factors contributing to this success and related outcomes. Within the session the authors will also discuss some of the challenging issues and decisions which other jurisdictions may face when considering smokefree policy.

The format of the workshop will comprise oral presentations by members of the study teams, followed by commentary by the discussant. It will begin with a brief overview of: a) the rationale for, and challenges of, implementing smokefree policies in the prison context; and b) the methods used during the studies. There will then be presentations examining: experiences and processes of implementing the smokefree prison policy in Scotland; the positive and negative consequences of making prisons smokefree; and use of e-cigarettes in the prison population.

Presenters: Dr Ashley Brown, Professor Kate Hunt, Dr Catherine Best

Discussant: Professor Linda Bauld


Friday 18th September 13.00-14.30 (CEST)

Smoking, vaping and COVID-19

There is substantial uncertainty around the impact of tobacco and nicotine use on COVID-19. On the one hand, there are good a priori reasons to assume that tobacco and vaping should be detrimental for infection, disease severity and mortality due to behavioural factors (frequent hand-to-mouth movement), actions on the immune system and increased likelihood of developing other diseases linked to worse COVID-19 outcomes. On the other hand, emerging evidence suggests lower than expected infection rates among smokers and lower smoking rates among those hospitalised with Covid-19, with little known about vaping. This has resulted in trials looking at the efficacy of nicotine use as a COVID-19 treatment. This symposium will provide an overview of current knowledge on how smoking and vaping impacts COVID-19 and vice versa to inform researchers and provide some guidance to policy makers and clinicians. Dr Perski will start by presenting the results of a living rapid review on the association of tobacco and nicotine use with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19. Given limitations in the current available evidence, posing considerable interpretational problems, Mr Simons will go on to describe results of a sizable case-control study from a single UK hospital site to elucidate the association between smoking and hospitalisation for COVID-19 using historic respiratory viral infections as a control. Dr Jackson will present data from a large online survey on the association of smoking with self-reported COVID-19 infection as well as with adherence to guidelines and worry about COVID-19, with a focus on socio-economic inequalities. Lastly, given the lack of data in this area, Dr Kale will present results from another online survey to assess the association of vaping with self-reported COVID-19 infection as well as associated changes in vaping behaviour due to COVID-19 related concerns and risk perceptions. Professor Brown will act as discussant for this symposium, bringing together results across these different studies, to explore implications for policy and practice when it comes to dealing with tobacco and nicotine use during this pandemic.

Presenters: Dr Olga Perski, David Simons, Dr Sarah E. Jackson, Dr Dimitra Kale

Discussant: Professor Jamie Brown


Friday 18th September 16.15-17.40 (CEST)

E-cigarettes and the clinical encounter

The clinical encounter is a key opportunity to promote smoking cessation, yet physicians inconsistently provide best-practices cessation advice due to lack of time, knowledge, skills, and confidence. Counseling smokers about cessation is complicated by smokers’ increasing use of e-cigarettes for cessation and the uncertainty surrounding their efficacy and health consequences. Furthermore, most smokers who use e-cigarettes do not switch completely to e-cigarettes, whether for harm reduction or as a step towards cessation. This symposium brings together studies of smokers and physicians across countries in order to characterize discussions about e-cigarettes in clinical encounters, results from an intervention to encourage these discussions in the context of cessation assistance, and to understand the consequences of these discussions.  Salloum will discuss results from a discrete choice experiment with primary care practitioners in the US, describing the physician and patient characteristics that drive physician recommendations for using e-cigarettes in the United States, where physician guidelines do not recommend e-cigarettes for cessation. Jackson will describe results from ongoing surveys with smokers in the UK – where health authorities have begun to embrace a harm reduction approach to e-cigarettes for established smokers - to describe trends in e-cigarette use recommendations, frequency of recommendation relative to other cessation methods, and their association with smoking cessation behaviors. Cho’s longitudinal study of smokers in four countries with contrasting regulatory environments (UK, US, Canada, Australia) examines trajectories in tobacco product use as a function of physician discussions about and recommendations to use e-cigarettes. Finally, Strayer will discuss results from a pre/post assessment of a clinic-based, iPad-delivered decision aid that tailors information to smokers about smoking cessation and e-cigarettes based on their quit intentions and e-cigarette use. Overall, these studies illustrate the panorama and complexity of the intersection between the clinical encounter, e-cigarettes, and smoking across regulatory environments.

Presenters: Dr Ramzi Salloum, Dr Sarah E. Jackson, Dr Yoo Jin Cho, Dr Scott Strayer

Discussant: Dr James F. Thrasher